Introduction
Proteins are in a dynamic state of synthesis and degradation. Two main mechanisms exist to degrade proteins inside eukaryotic cells: the lysosome and the proteasome. In general, lysosomes digest extracellular or cell surface proteins that are taken up by the cell, and some intracellular proteins that have been engulfed in autophagosomes. However, most targeted degradation of intracellular proteins is carried out by the proteasome. These include damaged or misfolded proteins, transcription factors, cell cycle regulators, and proteins from intracellular pathogens. Proteins are typically targeted to the proteasome by tagging with K48-linked polyubiquitin chains, which are attached to proteins though the action of E1 (ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin ligase) enzymes. Proteins can be rescued from proteasome-mediated degradation by deubiquitinases (DUBs). The proteasome, together with the Ub conjugation and deconjugation machinery, is referred to as the ubiquitin-proteasome system (UPS). The UPS not only recycles nonfunctional proteins but also controls a broad range of cellular processes though regulated proteolysis, including transcription, cell cycle progression, antigen presentation, apoptosis, and receptor-mediated endocytosis [1] .
The eukaryotic proteasome (26S proteasome) is a multisubunit ATP-dependent protease. It consists of the 20S core particle, which contains multiple protease active sites, and one or two proteasome activators, of which the 19S regulatory particle is the dominant form [2] (Fig. 1A) . The 19S cap contains subunits that recognize ubiquitinated proteins, which are then unfolded and deubiquitinated. The unfolded polypeptides are translocated into the 20S core, where proteolysis occurs to produce short peptides. The core particle consists of four rings of seven subunits: two outer rings of a subunits, and two inner rings of b subunits. The a subunits appear to have a regulatory or structural function. In archaea, all a subunits and all b subunits are identical, but higher organisms, including yeast, plants, and animals, have seven distinct a and seven distinct b subunits. Only the b1, b2, and b5 subunits are catalytically active (Fig. 1B) . All share an unusual protease mechanism in which the N-terminal threonine hydroxyl group attacks the scissile peptide bond (Fig. 1C) . The adjacent primary amine of the same residue acts as a general base, polarizing a nearby water molecule to deprotonate the hydroxyl during catalysis [3] . The b1, b2, and b5 subunits have distinct but overlapping selectivity. Based on experiments using fluorogenic substrates, b1 is referred to as 'caspase-like' (CL) or 'postglutamyl peptide hydrolyzing' (PGPH), b2 as 'trypsin-like' (TL), and b5 as 'chymotrypsin-like' (CTL), although these descriptions are undoubtedly an oversimplification [4] .
Specific patterns of catalytic subunits may be expressed and assembled into the core 20S complex in different tissues or after certain stimuli. This enables modulation of proteasome activity as well as changes in the types of peptides produced by the complex. There are also tissue-specific variations of the proteasome [5] (Fig. 1B) . Specifically, many cells of the immune system predominantly contain 'immunoproteasomes' in which the constitutively expressed catalytic subunits (b1c, b2c, and b5c) are replaced by interferon-induced immunoproteasome subunits (b1i, b2i, and b5i). In this review, reference to b1, b2, or b5, without the 'c' or 'i' suffix, implies both subunit types. Immunoproteasome expression can also be induced in nonimmune cells by proinflammatory cytokines. The immunoproteasome is thought to produce peptides that are optimized for binding to MHC class I molecules to increase the number of potential epitopes presented on the cell surface [6] . In particular, while b1c accepts peptides with an acidic P1 residue, b1i preferentially processes peptides with hydrophobic P1 residues which are required for efficient binding to MHC class I molecules [7] . The 'thymoproteasome' is a modification of the immunoproteasome, expressed only in the thymus, in which b5i is replaced with b5t. In addition to these three proteasome types, 'mixed' proteasomes can also form, containing both constitutive and immunoproteasome subunits. The formation and role of mixed proteasomes remains poorly understood [8] .
Application of probes to functional studies of proteasome activity
Assessing the activity of individual proteasome subunits is important in order to understand how the activity of the complex is regulated, to distinguish the roles of individual subunits, and to assess the efficacy and selectivity of proteasome inhibitors. Direct measurement of the overall abundance of individual proteasome subunits is a poor surrogate for activity because each of the catalytic subunits is expressed in an inactive form and a propeptide must be removed to generate the N-terminal catalytic Thr residue after assembly of the complex [9] . Additionally, proteasome activity is regulated by multiple proteins and cofactors [2] . Therefore, the activity of the proteasome is often assessed using peptide substrates or substrate mimics. Fluorogenic peptides are most commonly used for this purpose. These tri-or tetrapeptides contain a fluorophore (typically 7-amino-4-methylcoumarin, AMC) at the C terminus, which is nonfluorescent when linked to the peptide but becomes fluorescent when released by proteolytic cleavage [10] . Fluorogenic peptides with specificity for trypsin-like, chymotrypsinlike, or caspase-like activity are commercially available and can be used for kinetic studies of three main types of activities of the proteasome. However, the potential for 'selective' substrates to be processed by multiple subunits limits their use for studying the activity of individual subunits. Furthermore, substrates are not sufficiently selective to distinguish constitutive from immunoproteasome activity due to the highly similar specificity patterns for these subunits. Finally, extended fluorogenic peptide substrates are usually not cell permeable and their use in lysates (rather than with purified proteasomes) is often complicated by their propensity to be processed by other cellular proteases.
Activity-based probes (APBs) overcome many of the limitations of fluorogenic peptide substrates by reacting covalently and irreversibly with the proteasome active sites through an enzyme-catalyzed reaction. ABPs consist of 'three Rs': a reactive group, a recognition element, and a reporter tag [11] . For probes targeting Thr proteases, and other enzymes with active-site nucleophiles, the reactive group is an electrophile that forms a covalent bond to the active-site nucleophile. The recognition element typically mimics a substrate, and therefore can be made to selectively target an enzyme of interest, while the reporter tag is used to detect the labeled product of the reaction. ABPs therefore provide a significant advantage over substrate-based probes (such as fluorogenic peptides) as they allow direct identification of targets as well as direct monitoring of activity of individual subunits in the proteasome complex. As described below, ABPs have been developed that can distinguish all six types of constitutive and immunoproteasome subunits. They also show excellent selectivity for the proteasome over other proteases and in some instances can be used in live cells. In this review, we will highlight advances in the development of broad-spectrum and subunit-selective ABPs that target the proteasome. We will focus on the aspects of probe design that confer selectivity, and make them particularly suited for certain applications (e.g., in-cell detection or affinity purification). We will also discuss the applications of these probes in basic science and clinical research. This is not meant to be an exhaustive list of all studies using proteasome ABPs; rather, we wish to illustrate a range of highly valuable applications of these probes.
Proteasome ABPs
Proteasome ABPs are mechanism-dependent inhibitors that are modified to enable detection of the labeled catalytic subunits. With a few exceptions, all proteasome ABPs share a similar design ( Fig. 2A) , consisting of: (a) a reactive group ('warhead'), typically an epoxyketone (EK) or vinyl sulfone (VS), at the C terminus (Fig. 2B) ; (b) a tri-or tetrapeptide recognition element; (c) a reporter tag for detection (often a fluorophore), typically appended at the N terminus via a linker.
Consequently, the probes are frequently notated in the form label-linker-recognition element-warhead (e.g., BODIPY-Ahx 3 -L 3 -VS), or label-inhibitor (e.g., BODIPY-epoxomicin). Some laboratories apply their own systematic names: compounds from the Norris Cotton Cancer Center are NCxxy, where xx is a twodigit number, and y is the subunit inhibited (e.g., 1 for the b1 subunit), while compounds from Leiden University are LUxxy. However, nonsystematic names are also used (e.g., MV127), and probes may be referred to by different names in different publications, sometimes without reference to structures, making the literature somewhat confusing. For reference, chemical structures, probe names, and references are shown in Figs 3-6.
It is helpful to divide proteasome ABPs (and proteasome inhibitors) into two categories: 'broad-spectrum' (Fig. 3) , which are reactive toward most proteasome subunits, and 'subunit-selective' (Figs 4-6), which show a strong preference for a single subunit type. This should not be regarded as a hard distinction, as broad-spectrum probes will not react at an identical rate with all subunits, and 'subunit-selective' probes often inhibit other subunits when used at higher concentrations. Subunit-selective probes which can differentiate between constitutive and immunoproteasome subunits of a given type have only been reported recently (see below). Selectivity is often dependent on probe concentration and reaction time, which need to be optimized for the probe and system of interest. reactive groups with catalytic Thr residues of proteasome. Epoxyketones were initially believed to form cyclic morpholine adducts with the N-terminal Thr [71] , but recent high-resolution crystal structures suggest that the 1,4-oxazepane may be the preferred adduct [72] .
Biotin-Ahx 3 -epoxomicin [28] [ 125 I]YL 3 -VS [15] BODIPY(TMR)-epoxomicin (MBV003) [26] BMV037 [31] Ada-Ahx( -
Alkynyl-carfilzomib (OP-829) [32] Dansyl-Ahx 3 -L 3 -VS (DALVS) [21] 
Broad-spectrum ABPs
The earliest reported ABPs for the proteasome used a radiolabel for detection. The first reported probe, [ 14 C]-3,4-dichloroisocoumarin, was shown to label proteasome subunits. However, it also reacted broadly with serine and threonine proteases and so can only be effectively used with purified proteasomes [12, 13] . The N 3 -APnLL-VS-PhOH [37] BODIPY(FL)-LU001c ( 1c-selective) [40] az-NC001 [38] Cy5-LU001i ( 1i-selective) [40] LW124 (BODIPY-NC001) [39] (Cy5 analog also prepared [35] ) [14] . This cellpermeable compound showed good selectivity for the proteasome over other proteins. Remarkably, prior to this report, the VS warhead was thought to be highly selective for Cys proteases. Resolution of the ABPlabeled proteasome b-subunits by 1D SDS/PAGE failed to distinguish all the catalytic subunits, but use of 2D-SDS/PAGE enabled resolution of the subunits, including b1i and b5i. Replacing the nitrophenyl N-terminal cap with radioiodinated Tyr gave a more reactive probe ([   125   I ]-YL 3 -VS) which labeled all six constitutive and immunoproteasome catalytic subunits [15] . More generally, a hydrophobic P4 residue was found to be required for activity, and changes in the distal portion of the probe could substantially affect selectivity [16] . Building on these observations, Kesser et al. designed an 'extended' probe, Ada-[
125 I]Y-Ahx 3 -L 3 -VS. The large N-terminal extension increased potency and resulted in a probe that could label all catalytic subunits of both the constitutive and immunoproteasome. A biotin label was also introduced, but neither biotinylated nor radiolabeled probes were cell-permeable [17] , in contrast to the parent inhibitor Ada-Ahx 3 -L 3 -VS.
To overcome the problem of cell permeability, Ovaa et al. [18] turned to a two-step labeling procedure. An azide-containing analog of the inhibitor Ada-Ahx 3 -L 3 -VS labeled proteasome subunits in live cells. After lysis, a biotin label was attached by StaudingerBertozzi ligation [19] , and labeled proteasome subunits were detected by anti-biotin western blot. Alternatively, biotin-streptavidin affinity purification followed by tandem MS could be used to detect and identify labeled proteins [20] . Ovaa and coworkers subsequently reported a cell-permeable probe, dansyl-Ahx 3 -L 3 -VS (DALVS), that could be detected directly by immunoblot for the dansyl hapten [21] . However, the az-NC005 [38] LKS01-B650 ( 5i-selective) [73] BODIPY-NC005-VS (MVB127) [39] BODIPY(FL)-LU015c ( 5c-selective) [40] LU005 [74] BODIPY analog also prepared (PR592) [74] Cy5-LU035i ( 5i-selective) [40] dansyl group is excited by near-UV light and fluoresces with a low quantum yield. These properties make it unsuitable for sensitive detection of proteasome activity in cells by fluorescence microscopy, or by in-gel fluorescence detection (which could improve resolution and sensitivity by eliminating transfer and immunoblot steps). MV151 overcomes these shortcomings by appending the BODIPY(TMR) fluorophore to the same Ahx 3 -L 3 -VS inhibitory scaffold [22, 23] . BOD-IPY-containing probes are much more sensitive than the dansyl-containing probe, and can be used to label proteasome subunits in lysate, whole cells or even in vivo. They are also suitable for fluorescence microscopy and flow cytometry experiments [24] . Verdoes et al. [25] also developed an azide-containing analog of MV151, to which biotin can be attached after labeling. This allows both visualization of proteasome reactivity and enrichment of probe-labeled proteins.
Broad-spectrum ABPs containing recognition elements other than L 3 -VS have also been reported. Both fluorophore- [26, 27] and biotin-tagged [28, 29] analogs of the epoxyketone natural product epoxomicin have been prepared. Another proteasome-inhibiting natural product, syringolin A, has been prepared as a fluorophore conjugate [30] . For both compounds, the tagged analogs allowed identification of the proteasome as the biological target. These probes were also used to determine which subunits in the proteasome complex are targeted by each compound. These studies demonstrated that epoxomicin largely inhibits the b1 and b5 activity of the proteasome, while the preferred target of syringolin A is the b5 subunit, with somewhat weaker activity toward b2 and little effect on b1. Fluorophore- [31] and alkyne-tagged [32] analogs of the clinically approved proteasome inhibitor carfilzomib have also been reported, and the latter has been used to identify potential off-targets of the drug [32] .
The profile of probe reactivity is often dependent on the type of samples being analyzed as well as the conditions use for probe labeling. For example, experiments using multiple different classes of cell-permeable probes have shown that there is a substantial difference in the labeling profile between live cells and lysates, perhaps due to partial dissociation of the proteasome during lysis [18, 21, 22] . These observations highlight the importance of measuring activity in live cells where possible. Additionally, probe reactivity can vary between organisms. In mammalian cells, MV151 is proteasome-selective and pan-subunit reactive, whereas in Arabidopsis, it labels multiple cysteine proteases in addition to the proteasome [33] , and in Plasmodium falciparum, MV151 shows selective labeling of the b2 and b5 subunits [31] . It is therefore important to understand the specificity profiles of probes in the system of interest before using them to address proteasome function.
Subunit-selective ABPs
One of the major drawbacks in using broad-spectrum proteasome ABPs is the difficulty in distinguishing individual proteasome subunits. Notably, the b1c, b1i, b5c, and b5i subunits usually overlap on standard SDS/ PAGE gels. 2D-SDS/PAGE provides better resolution, but due to the tedious nature of the analysis, is not suitable for analyzing multiple samples simultaneously. Subunit-selective probes can provide information about a specific subunit of interest, or alternatively, can be multiplexed using probes with different reporters to analyze multiple subunits simultaneously [34, 35] .
b1-selective probes (Fig. 4) typically employ recognition elements based on the Ala-Pro-norLeu-Leu sequence, which was reported to be a b1 substrate by Kisselev et al. [36] . The first b1-selective probe (N 3 -APnLL-VS-PhOH) [37] used a phenolic vinyl sulfone warhead, previously shown to preferentially inhibit b1 sites [15] . Subsequently, an epoxyketone (NC-001) with the same peptide sequence was found to be more potent, without substantially affecting selectivity [38] . Both azide-tagged [37] and fluorophore-tagged [35, 39] analogs of NC-001 have been reported. Modifications of the recognition element allow generation of either b1c-or b1i-selective probes (BODIPY(FL)-LU001c and Cy5-LU001i) [35, 40] . A slightly different scaffold was used in the b1i-selective fluorescein-labeled probe UK101-Fluor, which uses an acylated lysine in P2, and a large hydrophobic moiety attached to the epoxide to mimic the P1 0 position. UK101-Fluor and its BODIPY analog were shown to be suitable for imaging b1i activity in live cells by fluorescence microscopy [41] .
Most b2-selective probes (Fig. 5 ) employ a basic amino acid in the P1 position, as expected from their trypsin-like substrate selectivity. Interestingly, a basic P3 residue is also favored by this subunit. The azidetagged epoxyketone probe az-NC-002 (az-LLR-EK) selectively labels the b2 subunits in cells, as confirmed by gel-based assay, and by tandem MS after biotinylation and affinity purification [42] . The RLR recognition element was more active against purified proteasomes, but less active in cells, presumably due to poor cell permeability. Geurink et al. subsequently reported that vinyl sulfones are more potent and selective toward the b2 subunits than their epoxyketone analogs [43] . Furthermore, replacement of arginine with the non-natural amino acid 4-(aminomethyl) phenylalanine in either the P1 site (LU012) [43] or P1 and P3 sites (LU112) further improved affinity and chemical stability. These compounds have an azide handle that can be used for attachment of biotin or a fluorophore after labeling. However, introduction of the fluorophore prior to labeling reduced selectivity over the b5 subunit [43] . Despite the trypsin-like selectivity of b5, a basic residue in the P1 site is not required. In the first example of a subunit-selective probe, Nazif and Bogyo showed that Ac-[
125 I]YRLN-VS selectively labeled b2, highlighting the importance of the P3 residue [16] . Recently, a b2c inhibitor bearing an azide group has been reported (LU-002c), but selectivity over the b2i subunit is modest [35] .
b5-selective probes (Fig. 6 ) have a preference for hydrophobic and aromatic residues in most positions, consistent with the chymotrypsin-like activity of this subunit. Both VS and EK warheads have been evaluated, with EKs typically showing greater reactivity but reduced selectivity over b1 and b2 subunits [39, 44] . Modification in the P1 and P3 positions can confer selectivity for either the b5c or b5i subunit: b5c favors a small hydrophobic group in P1 and a large hydrophobic group in P3, while b5i favors the reverse arrangement [35, 40, 45] .
It is notable that for all three subunit types, incorporation of non-natural amino acids has been essential to obtain highly subunit-selective inhibitors and probes. This is consistent with the observation that the individual proteasome subunits, in the context of the 20S core complex, have overlapping substrate specificities [17] . Selective probes must therefore explore chemical space outside of that provided by naturally occurring amino acids.
Uses of proteasome ABPs
Activity-based probes have played an important role during the development of proteasome inhibitors for cancer therapy. As described below, they were used to identify the epoxyketone moiety (now used in the drug carflizomib) as a selective proteasome-targeting electrophile, to study the selectivity and pharmacodynamics of proteasome inhibitors, and to examine acquired resistance to proteasome inhibitor treatment. Other examples described below highlight how ABPs have been used to identify the proteasome as a potential target in noncancer indications, and to study basic proteasome biology.
Target identification
Several natural products were identified as proteasome inhibitors through their derivatization into ABPs.
Lactacystin, the first natural product proteasome inhibitor identified, was prepared in tritiated form and used to track labeled proteins by fractionation, followed by Edman degradation [46] . This showed that the compound labeled the b5c and b5i subunits on their N-terminal threonine residues, helping to confirm that the N-terminal threonine is indeed the catalytic residue. Lactacystin is believed to cyclize to the b-lactone (Ormulide), which is then highly reactive toward the proteasome [47] . Subsequently, more potent b-lactone inhibitors have been identified, including salinosporamide A (marizomib), which is currently in phase I clinical trials.
The epoxyketone warhead, widely used in inhibitors, probes, and the drug carfilzomib, was first identified as a potent proteasome-targeting electrophile in the natural products epoxomicin and eponemycin [28, 29, 48, 49] . Biotinylated variants of these compounds were prepared in order to isolate their biological targets, revealing that epoxomicin targets the b2 and b5 proteasome subunits. More recent studies, using more sensitive MS techniques, showed that biotin-epoxomicin labels all six catalytic b subunits [26, 50] . Using biotinylated probes (for affinity purification followed by tandem MS to identify proteins) avoids the hazards of radioactivity and tedious fractionation used to identify targets.
Syringolin A (SylA) is a virulence factor produced by a strain of the bacterium Pseudomonas syringae that infects plants. It was initially shown to inhibit the eukaryotic constitutive proteasome based on experiments with fluorogenic substrates [51] , but a fluorescently tagged analog, Rh-SylA, was used to examine the its selectivity. These experiments revealed that SyrA targets all proteasome subunits, with a preference for the b5 and b2 subunits over b1 [52] . In mammalian cells, the compound also reacts with immunoproteasome subunits [30] .
Labeled versions of synthetic proteasome inhibitors have also been used to investigate proteasome selectivity. This has the advantage over competitive activitybased protein profiling (competitive ABPP, described below) of identifying nonproteasomal targets of the inhibitors. For example, azide-modified analogs of the subunit-specific inhibitors NC-001, NC-002, and NC-005 were used to demonstrate that the compounds were highly specific for the proteasome [38, 42] . The small azide label had minimal effect on activity, unlike larger fluorophore labels that can adversely affect activity or selectivity [43] . However, labeling was inferred from an anti-biotin blot, which lacks sensitivity. A more recent study employed an alkyne-modified analog of carfilzomib, combined with streptavidin-biotin affinity purification and tandem MS, to identify offtarget activity in cells. Only two nonproteasomal proteins (CYP27A1 and GSTO1) were confidently identified as carfilzomib targets. These experiments confirm the impressive selectivity of carfilzomib for its therapeutic targets, despite its reactive, electrophilic warhead [32] .
Competitive ABPP (compound screening and assessing selectivity)
Labeled ABPs for the proteasome are valuable tools for determining the selectivity of nonlabeled inhibitors, and for screening to identify novel subunit-selective inhibitors. In a typical competitive ABPP experiment, cells or lysate are first treated with a compound of interest, and then treated with a probe to label residual proteasome subunit activities. A reduction in probe labeling relative to an untreated control indicates that a compound targets that subunit.
In an important early application of competitive ABPP, Berkers et al. [21] used the probe DALVS to assess the activity of bortezomib toward different proteasome subunits in live cells. Bortezomib was initially designed as an inhibitor of b5 (chymotrypsin-like) activity [53, 54] . However, 20 nM bortezomib completely inhibited labeling of b5 and b1 subunits in MM.1S (multiple myeloma) cells after 2 h, with little effect on b2 activity, thus identifying the b1 subunit as an additional target of bortezomib. Several other reports using DALVS [55, 56] or Ada-[
125 I]-Ahx 3 -L 3 -VS [57] confirmed the selectivity of bortezomib toward the b1 and b5 subunits. DALVS was also used to monitor proteasome activity in PBMCs from a multiple myeloma patient receiving bortezomib treatment. b1 and b5 labeling was largely abolished 1 h post-treatment, but b2 labeling was also somewhat reduced. By 72 h, full proteasome activity was restored [58] . It should be noted that although bortezomib is a reversible inhibitor of the proteasome, its off-rate is very slow, and therefore it can compete for proteasome active sites with irreversible covalent probes. Competitive ABPP is unlikely to be suitable for evaluating the selectivity of reversible proteasome inhibitors with fast off-rates, such as the recently approved ixazomib (MLN9708) [59] .
Competitive ABPP has also been used to screen for novel proteasome inhibitors. Using broad-spectrum and substrate-specific ABPs, Li et al. demonstrated that Plasmodium and human proteasomes show differences in selectivity, and exploited these differences to identify compounds that selectively inhibit Plasmodium over human proteasome. While b5 inhibition is able to effectively block parasite replication, b2 inhibitors are less effective as a single agent but synergize with the antimalarial drug dihydroartemisinin. A combined b2/ b5 inhibitor showed single-agent efficacy in a rodent model of malaria [31, 60] .
As noted above, a combination of subunit-specific ABPs with different labels can increase the resolution of individual subunits in gel-based detection methods. This can be valuable for characterizing compound selectivity in competitive ABPP assays. Li et al. report a detailed protocol for quantifying the proteasome activity of all constitutive and immunoproteasome subunits using three cell-permeable fluorescently labeled probes: LW124 (b1), MVB127 (b5), and MVB003 (nonspecific). LW124 and MVB127 allow good resolution of b1c, b1i, b5c, and b5i activity, while the two b2 subunits are easily resolved with MVB003. Competitive ABPP demonstrated that bortezomib is a more potent inhibitor of b1i than b1c [50] . This selectivity could not have been detected with nonsubunit-specific probes, or with fluorogenic substrates (which cannot distinguish between constitutive and immunoproteasome activity). In a more recent publication from the same laboratory, the authors applied a cocktail of three subunit-selective probes, Cy5-NC-001 (b1), BODIPY(FL)-LU-112 (b2), and MVB127 (b5), to resolve all six subunits simultaneously in a gel-based assay. This assay was then used to screen for new subunit-selective inhibitors, leading to the identification of several compounds with selectivity for individual constitutive or immunoproteasome subunits [35, 45] .
Profiling proteasome activity across different conditions or stimuli
Proteasome ABPs have been particularly valuable in assessing how proteasome activity responds to changes in cellular conditions. Several studies have examined how proteasome activity changes after prolonged treatment with bortezomib, in an effort to understand mechanisms of resistance to proteasome inhibitors. Typically, cells are cultured with gradually increasing concentrations of drug until they are able to tolerate concentrations that kill the parental line, and then an ABP is used to assess proteasome activity. Using the DALVS probe, Kraus et al. observed that overall proteasome activity was increased in bortezomib-adapted HL-60 (AML) cells. This included the b2 subunit, which is not a target of bortezomib. Furthermore, bortezomib showed little inhibitory effect on proteasome activity in adapted cells, while NIP-L 3 -VS retained activity [58] . Other studies employing MV151 [61] or Rh-SylA [30] observed similar changes across adapted cell lines from different cancer types, including myeloma (the primary indication for bortezomib). Increased proteasome activity was coupled with an overall decrease in protein synthesis [61] . Bortezomib typically increases the amount of misfolded proteins, triggering the unfolded protein response (UPR) leading to apoptosis [62] . These results therefore suggest that cancer cells can become resistant to bortezomib by reducing protein synthesis and increasing protein degradation, to avoid triggering the UPR [61] . Interestingly, a b2-selective inhibitor in combination with b1/b5-targeting bortezomib or carflizomib could restore sensitivity in resistant cells, suggesting that b2 inhibitors may overcome resistance to current proteasome inhibitors [63] .
Aside from studying drug resistance mechanisms, ABPs have been used to characterize changes in proteasome activity during other disease-relevant processes. For example, using both nonselective and subunit-selective ABPs, Kammerl et al. observed a reduction in both immunoproteasome activity and MHC class I antigen presentation in response to cigarette smoke. As immunoproteasome activity is a ratelimiting step for MHC class I antigen presentation, the authors speculated that cigarette smoke-impaired immunoproteasome function reduces MHC I-driven immune responses, making smokers more susceptible to viral lung infections [64] . ABP experiments have also suggested a role for the proteasome in epithelialmesenchymal transition (EMT), an important developmental process that is also associated with metastasis [65] . A panel of fluorescent ABPs showed that b2c and b5c activity, but not b1c activity, were reduced during EMT. The authors subsequently showed that selective inhibition of b2 and b5 subunits promoted EMT and self-renewal. These findings suggest that proteasome inhibitors may, paradoxically, promote survival and metastasis in some cancer types. This contrasts with earlier studies using bortezomib, which found that proteasome inhibition suppressed metastasis [66] . Further study is required to clarify this potentially important effect of proteasome inhibitors.
Taken together, these experiments illustrate the power of ABPs to identify roles for the proteasome in the onset and progression of disease as well as in the response to treatment. The combination of ABPs with subunit-selective inhibitors is particularly valuable, as hypotheses about the involvement of particular proteasome subunits in a process can readily be tested with inhibitors.
Analyzing proteasome composition
How the makeup and activity of proteasome subunits affects proteasome function is not fully understood.
Techniques to identify the active subunits present in specific proteasome populations in a cell, or within an individual proteasome complex, will help to define the relationship between proteasome composition and activity. Biotin-and BODIPY-epoxomicin probes were used to demonstrate that while the b5t subunit is catalytically active, it has distinct substrate specify from the b5c or b5i subunits. Active b5t could be detected in the thymus from young and adult mice, but in no other tissues. ABPs were uniquely suited for these studies, as the b5t subunit activity could not be analyzed with fluorogenic substrates (b5c/b5i-selective substrates are not cleaved by b5t, and pan-reactive substrates do not distinguish between subunits) [26] .
Several groups have developed methods aimed at profiling proteasome composition. Western blotting, shotgun proteomics, or the ABPs described above can provide information about which subunits are present or active in a cell of interest, but cannot reveal the subunit composition of intact proteasomes. ABPs modified with a photocrosslinking group were reported by Geurnik, which can be used to isolate proteins found in proximity to active subunits. However, very few proteins were identified by this method [67] . Park et al. reported a FRET-based approach, where pairs of b1, b2, or b5-selective probes were tagged with FRET donor-acceptor pairs. A FRET signal between, for example, a Cy3-labeled b1 probe and a Cy5-labeled b5 probe would indicate that the b1 and b5 subunits are present in the same proteasome complex [68] . However, this method was hampered by the lack of probes that were able to distinguish constitutive from immunoproteasome subunits. Using a more extensive panel of selective probes, de Bruin et al. [40] identified populations of mixed proteasomes containing, for example, both b1i and b5c subunits.
Perspective
Far from simply being a 'trash can' for damaged proteins, the proteasome is a tightly regulated, heterogeneous protease complex with roles in controlling many cellular processes. However, how proteasome composition affects its activity is incompletely understood. The past two decades have produced a veritable 'toolbox' of ABPs to study the activity of all constitutive and immunoproteasome subunits, and also to identify which subunits are present simultaneously in the same complex. These tools will be useful to understand how proteasome composition and activity responds to stimuli, such as cytokines or infection. In particular, the FRET assay reported by de Bruin et al. is likely to be valuable for future studies of mixed proteasomes, whose function in protein homeostasis and antigenic peptide production is currently unclear [40] .
The proteasome is now a clinically validated target for several hematological cancers, and ABPs have played an important role in the development of these drugs, as described above. Recent work has identified parasite proteasomes as novel targets in infectious disease, including malaria, leishmaniasis, Chagas disease, and trypanosomiasis [60, 69] . The mycobacterial proteasome has also been investigated as a therapeutic target, and inhibitors selective for the Mycobacterium tuberculosis proteasome over the human proteasome have been developed [70] . In their work on the Plasmodium proteasome as an antimalarial target, Li et al. made extensive use of ABPs to identify subunit-selective inhibitors of the Plasmodium proteasome that showed selectivity over human proteasomes. ABPs have the potential to identify differences between pathogen and host proteasomes, and can thus be used to investigate the therapeutic potential of proteasome inhibitors in infectious disease. More generally, ABPs are likely to prove to be useful tools to investigate the proteasome as a target for other nononcology indications.
